INTRODUCTION
============

Rheumatoid arthritis (RA) is a chronic joint inflammatory disease with abnormal synovial hyperplasia that leads to tissue destruction and functional disability ([@b26-molce-39-8-611]). Fibroblast-like synoviocytes (FLS) are key effector cells in the pathogenesis of RA ([@b4-molce-39-8-611]). Previous reports have indicated that RA-FLS shares many properties with tumor cells: tumor-like proliferation, migration, and invasion, as well as increased resistance to apoptosis ([@b4-molce-39-8-611]; [@b14-molce-39-8-611]). The invasion of FLS in RA is considered to be as aggressive as in tumor cells ([@b30-molce-39-8-611]). FLS have inherent invasive qualities not observed in other fibroblasts. A previous study has demonstrated that intimal fibroblasts can invade articular cartilage even in the absence of immune cells because of these unusual properties ([@b11-molce-39-8-611]). Synoviocyte migration also was found to be partly responsible for spreading arthritic destruction to distant joints ([@b16-molce-39-8-611]). Therefore, understanding the mechanism regulating the migration and invasion of FLS in RA may provide novel treatment strategies.

Follistatin-like protein-1 (FSTL1) was first identified as a transforming growth factor β1-inducible protein, which is a secreted extracellular glycoprotein containing a follistatin-like and extracellular calcium-binding domain ([@b33-molce-39-8-611]). Previous studies revealed a substantial connection between FSTL1 levels and RA severity ([@b5-molce-39-8-611]). Some studies identified FSTL1 as a new pro-inflammatory mediator that contributes to RA by promoting the expression of tumor necrosis factor-α, interleukin-1β, interleukin-6, and interleukin-8, as well as by enhancing the interferon-γ signaling pathway in a mouse model ([@b5-molce-39-8-611]; [@b7-molce-39-8-611]). In this study, we observed aberrant levels and significant effects of FSTL1 in RA -FLS.

MiRNAs are endogenous, small (21--25 nucleotides), single-stranded, non-coding RNAs that mediate mRNA cleavage, translational repression, and mRNA destabilization ([@b23-molce-39-8-611]). It has been reported that alterations in miRNA expression levels impact the expression of target genes in a 1.0-fold to 4-fold manner, which indicates that a fine-tuning mechanism regulates protein expression ([@b29-molce-39-8-611]). The altered expression of circulating miRNAs in RA-FLS has been reported repeatedly ([@b13-molce-39-8-611]; [@b28-molce-39-8-611]; [@b35-molce-39-8-611]). In particular, previous reports have demonstrated that miR-27a has key roles in the migration and invasion of cancer cells ([@b19-molce-39-8-611]; [@b31-molce-39-8-611]). A recent study showed that miR-27a was dysregulated in chondrocytes in osteoarthritis ([@b34-molce-39-8-611]). However, the role of miR-27a in RA has remained elusive.

Matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases, are the main proteases responsible for the invasion and degradation of basement membranes and extracellular matrix. MMP2, MMP9, and MMP13 are key members of the MMP family that can cleave gelatin and facilitate cell migration and invasion ([@b38-molce-39-8-611]). It has been demonstrated that herbal extracts inhibit human umbilical vein endothelial cell invasion and migration by regulating MMP2 and MMP9 ([@b8-molce-39-8-611]; [@b32-molce-39-8-611]). RA-FLS can erode cartilage by synthesizing and secreting MMPs ([@b1-molce-39-8-611]), thus representing a potential target for RA therapy. The Rho family of small GTPases forms a 20-member family within the Ras superfamily of GTP-dependent enzymes that are activated by a variety of extracellular signals. RhoA, Cdc42, and Rac1, the most well-known Rho family members ([@b22-molce-39-8-611]; [@b37-molce-39-8-611]), all have been reported to play important roles in the migration and invasion of various cells ([@b24-molce-39-8-611]).

In our study, the expression of MMPs (MMP2, MMP9, MMP13) and Rho family members (RhoA, Cdc42, Rac1) may be associated with the cell migration and invasion of RA-FLS. Therefore, we analyzed aberrant expression of miRNA-27a and FSTL1 in RA patients and then focused on the effects of miR-27a on RA-FLS migration and invasion. The mechanism of miR-27a-mediated migration and invasion-related protein expression was also determined in RA-FLS.

MATERIALS AND METHODS
=====================

Preparation of human serum, synovial tissues, and fibroblast-like synoviocytes
------------------------------------------------------------------------------

This study was performed according to the recommendations of the Declaration of Helsinki and approved by the Medical Ethical Committee of the Henan Province Hospital of TCM in Henan, China. Serum and synovial tissue samples were obtained from patients with RA (10 women and 8 men, 40--68 years old) who were undergoing synovectomy or joint replacement at the hospital. Eighteen healthy subjects (12 men and 6 women; age range, 38--65 years old) were used as normal controls. All patients provided their informed consents to participate in the study. RA was diagnosed according to the 2010 ACR/European League against Rheumatism classification criteria for RA ([@b2-molce-39-8-611]). Synovial tissue samples were cut into small pieces and digested with 1 mg/ml collagenase for 3 h at 37°C to isolate synoviocytes. RA-FLS and human embryonic kidney 293 cells were cultured in DMEM/F12 with 10% FBS, 100 units/ml penicillin, and 100 μg/ml streptomycin at 37°C and 5% CO~2~, as previously described ([@b24-molce-39-8-611]). In our experiments, cells were used at passages from 3 to 6, during which time they were a homogeneous population of cells.

Enzyme-linked immunosorbent assay (ELISA)
-----------------------------------------

Serum FSTL1 levels were measured using a standard quantitative sandwich ELISA (eBioscience, Austria). All analyses and calibrations were performed in triplicate.

Cell transfection of miR-27a mimic and inhibitor
------------------------------------------------

FLS were seeded into 24-well or 6-well plates 24 h prior to transfection. MiRNA control mimic, miR-27a mimic, miRNA control inhibitor, and miR-27a inhibitor (Applied Biosystems, USA) were transfected at a final concentration of 80 nM with Lipofectamine 2000 (Invitrogen, USA). The cells were harvested at 24 h for RNA extraction and at 48 h for protein extraction.

Cell migration and invasion assays
----------------------------------

The cell migration assay was performed with Transwell chambers with 8-μm pores (Corning, USA). FLS (1 × 10^5^ cells per chamber) were plated in the upper chambers in duplicate filters. DMEM containing 10% FBS was added to the lower chamber as a chemoattractant. FLS were suspended in serum-free DMEM in the upper chambers. Forty-eight hours after transfection with the miR-27a mimic or miR-27a inhibitor, non-migrating cells were removed from the upper surface, and filters were stained with crystal violet. Migrated cells were counted in five representative microscopic fields (100× magnification).

Cell invasion ability was assessed using Matrigel invasion chambers (BD Biosciences, USA). FLS (5 × 10^4^ cells per chamber) were seeded onto Matrigel Transwell chambers pre-coated with Matrigel (BD Biosciences). The lower chambers were filled with DMEM medium containing 10% FBS, and the FLS in the upper chambers were filled with serum-free DMEM. Forty-eight hours after transfection with the miR-27a mimic or miR-27a inhibitor, cells on the top membrane surface were removed. Cells that penetrated to the bottom were stained with crystal violet and counted, as previously described.

Construction of adenoviral vector expressing FSTL1
--------------------------------------------------

The wild-type FSTL1 cDNA sequence without the 3′UTR was subcloned into an adenovirus shuttle vector. After linearization, the shuttle vector was co-transformed into Escherichia coli with the adenoviral backbone plasmid pAdEasy-1 (Stratagene, USA). The resultant recombinant adenoviral DNA with FSTL1 cDNA was transfected into human embryonic kidney 293 cells to produce the recombinant adenoviral vector. An adenoviral vector expressing β-galactosidase (Ad-βgal) was used as a control. Adenoviral vectors were purified by CsCl ultracentrifugation.

Quantitative reverse transcription-PCR
--------------------------------------

Total RNA was extracted from both synovial tissues and FLS with TRIzol reagent (Invitrogen). For mRNA quantification, 500 ng of RNA were used for the synthesis of cDNA with reverse transcriptase using the M-MLV First Strand Kit (Taraka, China), according to the manufacturer's instructions. One microliter of cDNA was used for real-time PCR with GoTaq qRT-PCR Master Mix (Promega, USA). For each sample, the relative mRNA level was normalized to β-actin expression. [Table 1](#t1-molce-39-8-611){ref-type="table"} lists the primers for qRT-PCR.

For miRNA quantification, the GoScript Reverse Transcription System Kit (Promega) was used with the stem loop primer. For each sample, the relative mRNA level was normalized by U6. The forward and reverse primers for miR-27a were 5′-UUCACAGUGGCUAAGUUCCGC-3′ and 5′-GGAACUUAGCC ACUGUGAAUU-3′. Relative expression levels of miRNA or mRNA were analyzed using the Bio-Rad C1000 Thermal Cycler (Bio-Rad, USA).

Western blot
------------

Total membranes and nuclear extracts were prepared as described previously, and protein concentrations were determined using the BCA assay (Pierce, USA). The dilution of primary antibodies was as follows: MMP2 (MA1-772, 1:500); MMP9 (MA5-14220, 1:500); MMP13 (MA5-14247, 1:350); FSTL1 (PA5-31113, 1:1500); Rac1 (PA1-091, 1:1000); Cdc42 (PA1-092X, 1:1000); RhoA (MA1-011, 1:1000); TLR4 (MA5-16216, 1:1000); and NF-κB (PA1-186, 1:1000). All primary antibodies were detected with rabbit polyclonal antibodies (Invitrogen). Each membrane was rinsed three times for 15 min and incubated with the secondary horseradish peroxidase-linked antibodies. β-actin was used as the loading reference for data analysis.

Luciferase reporter assay
-------------------------

The human FSTL1 3′-UTR was amplified and cloned into the XbaI site of the pGL3-control vector (Invitrogen), downstream of the luciferase gene, to generate the pGL3-FSTL1-3′UTR plasmid. In addition, pGL3-FSTL1-3′UTR-mut plasmids were constructed using cDNA fragments containing corresponding mutated nucleotides for miR-27a as a control. For the luciferase reporter assay, FLS were co-transfected with 100 ng of the luciferase reporter vectors and 20 pmol of control mimic, miR-27a mimic, control inhibitor, or miR-27a inhibitor using Lipofectamine 2000 (Invitrogen). The β-actin promoter *Renilla luciferase* reporter was used for normalization. After 48 h, luciferase activity was analyzed using the Dual-Luciferase Assay System (Promega).

Statistical analysis
--------------------

All data are expressed as the mean ± SD of results derived from three independent experiments performed in triplicate. Statistical analysis was performed by Student's *t*-test and ANOVA. A difference was accepted as significant if *p* \< 0.05.

RESULTS
=======

MiR-27a expression is downregulated and FSTL1 expression is upregulated in the serum, synovial tissue, and fibroblast-like synoviocytes of rheumatoid arthritis patients
------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The miR-27a expression and FSTL1 levels in the serum, synovial tissue, and FLS of RA patients and healthy controls were determined using qRT-PCR and Western blot analysis. It was found that FSTL1 expression in the serum, synovial tissue, and FLS was significantly elevated in RA patients, compared to healthy controls ([Fig. 1A](#f1-molce-39-8-611){ref-type="fig"}). A microRNA database was used to screen miRNA candidates targeted to FSTL1 ([@b10-molce-39-8-611]). As a candidate target miRNA of FSTL1, significantly decreased expression of miR-27a was shown in the serum, synovial tissue, and FLS of RA patients, compared to healthy controls ([Fig. 1B](#f1-molce-39-8-611){ref-type="fig"}). These data suggest that a decrease in miR-27a expression and an increase in FSTL1 expression may be involved in the development of RA.

MiR-27a overexpression reduces cell migration and invasion of RA FLS
--------------------------------------------------------------------

Cell migration and invasion were detected in RA-FLS after the transfection of the miR-27a mimic or miR-27a inhibitor. The expression of miR-27a was significantly increased by transfection with miR-27a but significantly reduced by transfection with the miR-27a inhibitor ([Fig. 2A](#f2-molce-39-8-611){ref-type="fig"}), suggesting that the transfection efficiency was sufficient for further analysis. The results of the Transwell assay showed that the miR-27a mimic significantly inhibited cell migration and invasion of RA-FLS, whereas the miR-27a inhibitor promoted FLS migration and invasion in RA ([Figs. 2B and 2C](#f2-molce-39-8-611){ref-type="fig"}). These data suggest that miR-27a inhibits cell migration and invasion of RA-FLS.

MiR-27a overexpression inhibits the expression of migration and invasion-related proteins in RA-FLS
---------------------------------------------------------------------------------------------------

To further determine the role of miR-27a in cell migration and invasion, the expression of migration and invasion-related proteins was detected by using western blot and qRT-PCR. It was shown that the expression of MMP2, MMP9, and MMP13 proteins was reduced by miR-27a, Whereas their expression was upregulated by miR-27a inhibitor. The qRT-PCR results indicated that MMP2, MMP9, and MMP13 mRNA levels were down-regulated by miR-27a, as observed for protein levels in transfected FLS ([Figs. 3A and 3B](#f3-molce-39-8-611){ref-type="fig"}). In addition, miR-27a reduced the expression of Rac1, Cdc42, RhoA protein, and mRNA, which was upregulated by the miR-27a inhibitor ([Figs. 3C and 3D](#f3-molce-39-8-611){ref-type="fig"}). These findings imply that miR-27a inhibits the expression of migration and invasion-related proteins in RA-FLS.

MiR-27a directly targets FSTL1 expression
-----------------------------------------

In our study, FSTL1 was identified as a potential miR-27a target gene. To verify the binding site, the 3′-UTR of FSTL1 containing the wild type or mutated seed-sequence of miR-27a was cloned for use in a firefly luciferase reporter assay ([Fig. 4A](#f4-molce-39-8-611){ref-type="fig"}). Compared with the control and the miR-27a inhibitor, miR-27a significantly inhibited relative luciferase activity when co-transfected with the FSTL1-UTR reporter plasmid. However, miR-27a-mediated inhibitory effects were not observed in the mutant reporter transfected cells ([Fig. 4B](#f4-molce-39-8-611){ref-type="fig"}). Western blot results showed that the protein expression of FSTL1 was decreased in miR-27a-transfected RA FLS and increased in miR-27a inhibitor-transfected RA FLS ([Fig. 4C](#f4-molce-39-8-611){ref-type="fig"}). These results suggest that miR-27a may suppress FSTL1 expression by directly binding to the 3′-UTR of FSTL1.

FSTL1 overexpression rescues the miR-27a-mediated suppressive effect on RA-FLS migration and invasion by activating the TLR4/NFκB pathway
-----------------------------------------------------------------------------------------------------------------------------------------

Previous studies show that miR-27a attenuated inflammatory damage by negatively regulating the TLR4/NFκB pathway ([@b20-molce-39-8-611]; [@b25-molce-39-8-611]). Thus, to evaluate the role of TLR4/NFκB signaling in RA-FLS migration and invasion, we examined the cell migration and invasion of RA-FLS, as well as the levels of TLR4 and NFκB in RA-FLS, which had been transfected with miR-27a and exogenous FSTL1. The results described herein showed that miR-27a reduced cell migration and invasion of RA-FLS, whereas these effects were restored by the eukaryotic expression and vector-mediated delivery of FSTL1 ([Fig. 5A](#f5-molce-39-8-611){ref-type="fig"}). Furthermore, miR-27a downregulated the mRNA and protein expression of TLR4 and NFκB, but overexpression of FSTL1 significantly counteracted this inhibitory effect ([Fig. 5B](#f5-molce-39-8-611){ref-type="fig"}). Taken together, these data indicate that overexpression of FSTL1 abrogates the reduction in miR-27a-reduced TLR4/NFκB activation and suggest that FSTL1 is a functional mediator of the effects of miR-27a in RA-FLS.

DISCUSSION
==========

RA is an autoimmune disease correlating with the pathological features of joint synovial inflammation. FSTL1 is widely considered to participate in the development and pathogenesis immune diseases as a secreted extracellular glycoprotein ([@b5-molce-39-8-611]). MiRNA is a set of noncoding small RNA molecules found in recent years ([@b17-molce-39-8-611]) that can regulate post-transcriptional mRNA expression and a variety of immune cell activation and differentiation processes ([@b9-molce-39-8-611]). It has been reported that miRNAs affect the proliferation and invasion of RA-FLS ([@b35-molce-39-8-611]). Notably, miR-27a was dysregulated in the chondrocytes of osteoarthritis ([@b34-molce-39-8-611]). However, the role of miR-27a in RA remains unclear. Our preliminary data showed that the expression of miR-27a, a candidate target miRNA of FSTL1, was significantly decreased in the serum, synovial tissue, and FLS of RA patients, compared with healthy controls. Considering the downregulation of miR-27a in RA patients, it may have a critical role in RA development. Thus, we investigated whether miR-27a could suppress the migration and invasion of RA-FLS and migration-related protein expression by targeting FSTL1.

RA-FLS is the major cell population involved in the development of RA in synovial tissues. Previous studies have shown that RA-FLS migrate and invade the cartilage and bone, contributing to pannus formation and tissue damage during RA progression ([@b16-molce-39-8-611]). Therefore, modulation of RA-FLS migration and invasion may offer a novel strategy for RA therapy ([@b18-molce-39-8-611]). Prior studies indicated that the suppression of FLS migration and invasion might protect against joint destruction in RA ([@b15-molce-39-8-611]). It has been demonstrated that miR-27a mimics impaired the invasive ability of human malignant glioma cell lines ([@b6-molce-39-8-611]; [@b19-molce-39-8-611]). Our study suggested that miR-27a inhibited the cell migration and invasion of RA-FLS. However, the inhibition of miR-27a suppressed the migration and invasion of breast cancer cells ([@b39-molce-39-8-611]). Thus, the effects of miR-27a on cell migration and invasion may vary in different tissues.

Previous studies have shown that MMPs produced by RA-FLS are involved in the development and progression of RA ([@b36-molce-39-8-611]). MMP13 promotes bone destruction in RA ([@b40-molce-39-8-611]). In addition, endogenous MMP2 and MMP9 contribute to synovial fibroblast survival, proliferation, migration, and invasion in RA ([@b32-molce-39-8-611]). Increased activation of RhoA was found in *ex vivo* FLS from RA patients, as compared with those of healthy controls. The inhibition of RhoA activity could suppress the cytoskeletal reorganization and proliferation of RA-FLS. As the most well-known Rho family member, Rac1 has been reported to inhibit RA-FLS proliferation and invasion ([@b21-molce-39-8-611]). Previous studies have indicated that downregulation of RhoA and Cdc42 inhibits the invasion and migration of osteosarcoma cells ([@b12-molce-39-8-611]). The present study showed that miR-27a suppressed expression of MMPs and Rho family members and inhibited RA-FLS migration and invasion. These findings indicate that the attenuation of FLS migration and invasion induced by miR-27a may be achieved by inhibiting MMP and Rho family protein expression.

To further investigate the role of miR-27a in RA-FLS migration and invasion, RA-FLS were transfected with miR-27a and exogenous FSTL1. The results showed that miR-27a reduced the migration and invasion of RA-FLS, whereas the effects were restored by FSTL1 overexpression. There is increasing evidence that toll-like receptors play a key role in the development of RA in response to molecules of microbial origin found in the joints of RA patients. It has been demonstrated that FSTL1 can bind to CD14 via TLR4 ([@b27-molce-39-8-611]). Toll-like receptor signaling pathways culminate with activation of transcription factor NFκB and of mitogen-activated protein kinases JNK and p38. The control of toll-like receptor expression occurs at various levels, including post-transcriptionally; miR-NAs have emerged as a new class of toll-like receptor regulators. TLR4 mRNA regulation by members of the let-7 miRNA family has been reported ([@b3-molce-39-8-611]). A previous study showed that miR-27a attenuates inflammatory damage by negatively regulating the TLR4/NFκB pathway ([@b20-molce-39-8-611]). The elevated level of serum FSTL1 suggests that the molecule is a potential serum marker related to the severity of joint damage in RA, perhaps by promoting RA-FLS migration and invasion. Our results showed that the TLR4/NFκB pathway was inhibited by miR-27a; the effects of miR-27a also were inhibited by FSTL1 overexpression. These data suggest that FSTL1 is a functional mediator of the effects of miR-27a in RA-FLS. Moreover, considering the miR-27a downregulation and FSTL1 upregulation observed in RA patients, we propose that FSTL1 is a target gene of miR-27a in RA-FLS. Our findings suggest that miR-27a regulates the expression of FSTL1 in both mRNA and protein levels by directly binding to the 3′-UTR of FSTL1.

In conclusion, we have found that the novel microRNA miR-27b functions as a RA-FLS migration and invasion suppressor. This suppression is associated with downregulation of MMPs and Rho family proteins in RA-FLS cells. In addition, the effects of miR-27b may depend on targeting FSTL1 with the inactivation of the TLR-4/NFκB pathway. Thus, our study provides evidence showing that miR-27a may be a useful target for the management of RA.

![Expression of miR-27a and FSTL1 in RA serum, synovial tissue, and FLS. (A) The serum expression of FSTL1 of RA patients was validated by ELISA, and its level in synovial tissue and FLS was validated by western blot and qRT-PCR. (B) The expression of miR-27a was validated in serum, synovial tissue, and FLS of RA patients by qRT-PCR. ^\*\*^*p* \< 0.01, versus control group.](molce-39-8-611f1){#f1-molce-39-8-611}

![Effects of miR-27a on the cell migration and invasion of RA-FLS. (A) The expression of miR-27a was detected by qRT-PCR after the transfection of miR-27a or miR-27a inhibitor. (B) RA-FLS migration was measured using the Transwell system after transfection with the miR-27a mimic or miR-27a inhibitor. (C) RA-FLS invasion was measured using the Transwell system after transfection with the miR-27a mimic or miR-27a inhibitor. ^\*^p \< 0.05, versus control group.](molce-39-8-611f2){#f2-molce-39-8-611}

![Effects of miR-27a on the expression of migration and invasion-related proteins in RA-FLS. RA-FLS were transfected with miR-27a mimic or miR-27a inhibitor. (A) The protein and mRNA expression of MMP2, MMP9, and MMP13 in RA-FLS was detected by western blot and qRT-PCR assay. (B) The protein and mRNA expression of Rac1, Cdc42, and RhoA in RA-FLS was detected by western blot and qRT-PCR assay. ^\*^*p* \< 0.05, versus control mimic group. ^\#^*p* \< 0.05, versus control inhibitor group.](molce-39-8-611f3){#f3-molce-39-8-611}

![Identification of FSTL1 as a target of miR-27a. (A) A luciferase reporter with either the wild-type or mutant sequences of FSTL1 3′UTR was constructed according to the sequence of the miR-27a binding site within the 3′UTR of human FSTL1, using the pGL3 vector. (B) For the luciferase reporter assay, FLS were co-transfected with the luciferase reporter vectors and control mimic, miR-27a mimic, control inhibitor, or miR-27a inhibitor. Relative luciferase activity in RA-FLS was measured after a 48-h transfection. (C) Western blot analysis was used to evaluate the expression of FSTL1 in RA-FLS after transfection with miR-27a mimic or miR-27a inhibitor. ^\*^*p* \< 0.01 versus control group.](molce-39-8-611f4){#f4-molce-39-8-611}

![FSTL1 overexpression rescues the miR-27a-mediated suppressive effect on RA-FLS migration and invasion by activating the TLR4/NFκB pathway. RA-FLS were transfected with miR-27a, exogenous FSTL1, or miR-27a and exogenous FSTL1. (A) The cell migration and invasion of RA-FLS as measured using the Transwell system. (B) Protein expression levels of TLR4 and NFκB in RA-FLS were detected by western blot analysis. ^\*^*p* \< 0.05, versus control mimic group. ^\#^*p* \< 0.05, versus Ad-β-gal group. ^a^*p* \< 0.05, versus miR-27a mimic group.](molce-39-8-611f5){#f5-molce-39-8-611}

###### 

RT-PCR primer sequences

  -------------------------------------------
  GENE        Primer sequences (5′-3′)
  ----------- -------------------------------
  FSTL1       F: CCAGAACTATGATAATGGAGACGCT\
              R: TAAGATGAACTATGAACCTCCTGCC

  MMP2        F: CCGTCGCCCATCATCAAGTT\
              R: CTGTCTGGGGCAGTCCAAAG

  MMP9        F: TCCTGGTGCTGGCTTGCTGC\
              R: CAATGTCAGCTTCGGGGCCG

  MMP13       F: TGATGAAACCTGGACAAGCA\
              R: TCCTCGGAGACTGGTAATGG

  Rac1        F: GTAAAACCTGCCTGCTCATC\
              R: GCTTCGTCAAACACTGTCTTG

  Cdc42       F: GCAGGGCAAGAGGATTATGA\
              R: GGTCCCGACAAGCAAGAAA

  RhoA        F: CATCCCAGAAAAGTGGACTCCA\
              R: CCTTGTGTGCTCATCATTCCG

  TLR4        F: CAGCTCTTGGTGGAAGTTGA\
              R: GCAAGAAGCATCAGGTGAAA

  NF-κB p65   F: CTCTGCTTCCAGGTGACAGT\
              R: TCCTCTTTCTGCACCTTGTC

  β-actin     F: GTGGGGCGCCCCAGGCACCA\
              R: CTCCTTAATGTCACGCACGATTTC
  -------------------------------------------

F, Forward sequences; R, Reverse sequences
